These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11563596)

  • 1. Successful lamivudine therapy for post-chemotherapeutic fulminant hepatitis B in a hepatitis B virus carrier with non-Hodgkin's lymphoma: case report and review of the literature.
    Kawai Y; Ikegaya S; Hata M; Kawahito M; Imamura S; Yoshida A; Tsutani H; Ueda T
    Ann Hematol; 2001 Aug; 80(8):482-4. PubMed ID: 11563596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine.
    Simpson ND; Simpson PW; Ahmed AM; Nguyen MH; Garcia G; Keeffe EB; Ahmed A
    J Clin Gastroenterol; 2003 Jul; 37(1):68-71. PubMed ID: 12811213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful long-term control with lamivudine against reactivated hepatitis B infection following intensive chemotherapy and autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma: experience of 2 cases.
    Nakagawa M; Simizu Y; Suemura M; Sato B
    Am J Hematol; 2002 May; 70(1):60-3. PubMed ID: 11994984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma.
    Stroffolini T; Andriani A; Bibas M; Barlattani A
    Ann Hematol; 2002 Jan; 81(1):48-9. PubMed ID: 11807636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
    Rossi G; Pelizzari A; Motta M; Puoti M
    Br J Haematol; 2001 Oct; 115(1):58-62. PubMed ID: 11722410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma.
    Clark FL; Drummond MW; Chambers S; Chapman BA; Patton WN
    Ann Oncol; 1998 Apr; 9(4):385-7. PubMed ID: 9636828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined lamivudine and interferon-alpha therapy for chemotherapy-induced reactivation of hepatitis B virus.
    Ohmoto K; Tsuduki M; Yamamoto S
    Am J Gastroenterol; 2003 May; 98(5):1215-6; author reply 1217. PubMed ID: 12809863
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature.
    Al-Taie OH; Mörk H; Gassel AM; Wilhelm M; Weissbrich B; Scheurlen M
    Ann Hematol; 1999 May; 78(5):247-9. PubMed ID: 10391107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effective treatment with Lamivudine of patients with reactivation of hepatitis B following chemotherapy administration].
    Shtalrid M; Haran M; Klepfish A; Lurie Y; Malnick S
    Harefuah; 2001 Dec; 140(12):1159-62, 1230, 1229. PubMed ID: 11789300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
    Endo T; Sakai T; Fujimoto K; Yamamoto S; Takashima H; Haseyama Y; Nishio M; Koizumi K; Koike T; Sawada K
    Bone Marrow Transplant; 2001 Feb; 27(4):433-6. PubMed ID: 11313673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus reactivation in a patient undergoing steroid-free chemotherapy.
    Shimizu D; Nomura K; Matsumoto Y; Ueda K; Yamaguchi K; Minami M; Itoh Y; Horiike S; Morita M; Taniwaki M; Okanoue T
    World J Gastroenterol; 2004 Aug; 10(15):2301-2. PubMed ID: 15259089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy.
    Lee GW; Ryu MH; Lee JL; Oh S; Kim E; Lee JH; Kim SB; Kim SW; Suh C; Lee KH; Kim WK; Lee JS; Kang YK
    J Korean Med Sci; 2003 Dec; 18(6):849-54. PubMed ID: 14676442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
    Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
    JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lamivudine and glycyrrhizin for treatment of chemotherapy-induced hepatitis B virus (HBV) hepatitis in a chronic HBV carrier with non-Hodgkin lymphoma.
    Matsuo K; Takenaka K; Shimomura H; Fujii N; Shinagawa K; Kiura K; Harada M
    Leuk Lymphoma; 2001 Mar; 41(1-2):191-5. PubMed ID: 11342373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: a case report and review of the literature.
    Saif MW; Little RF; Hamilton JM; Allegra CJ; Wilson WH
    Ann Oncol; 2001 Jan; 12(1):123-9. PubMed ID: 11249039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
    Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
    Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
    Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
    Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.
    Leaw SJ; Yen CJ; Huang WT; Chen TY; Su WC; Tsao CJ
    Ann Hematol; 2004 May; 83(5):270-5. PubMed ID: 15060745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.
    Kim JS; Hahn JS; Park SY; Kim Y; Park IH; Lee CK; Cheong JW; Lee ST; Min YH
    Yonsei Med J; 2007 Feb; 48(1):78-89. PubMed ID: 17326249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation.
    Silvestri F; Ermacora A; Sperotto A; Patriarca F; Zaja F; Damiani D; Fanin R; Baccarani M
    Br J Haematol; 2000 Feb; 108(2):394-6. PubMed ID: 10691871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.